AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

November 19, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 19, 2019--

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in triple-negative breast cancer (TNBC) in a poster presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS), taking place December 10-14 in San Antonio, Texas.

The abstract for this presentation is now available online on the SABCS website at https://www.sabcs.org.

Details of the presentation are as follows:

Presentation Title: Epigenomic analysis of cancer stem cells (CSCs) from triple-negative breast cancer (TNBC) reveals p63 and p73 as core metastasis drivers
Session Date & Time: Friday, December 13, 7:00 a.m. – 9:00 a.m. CT (8:00 a.m. – 10:00 a.m. ET)
Session Title: Poster Session 4
Presenter: Matthew G. Guenther, Ph.D., Syros
Abstract Number: 2254
Program Number: P4-04-02
Location: Henry B. Gonzalez Convention Center, Hall 1

About Syros Pharmaceuticals:
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline of development candidates, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in investigational new drug application-enabling studies in cancer. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases, including sickle cell disease. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191119005169/en/

CONTACT: Media Contact:

Naomi Aoki

Syros Pharmaceuticals, Inc.

617-283-4298

naoki@syros.com

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

KEYWORD: TEXAS MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH STEM CELLS GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Syros Pharmaceuticals

Copyright Business Wire 2019.

PUB: 11/19/2019 07:01 AM/DISC: 11/19/2019 07:01 AM

http://www.businesswire.com/news/home/20191119005169/en